about
Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathySubclinical Alterations of Cardiac Mechanics Present Early in the Course of Pediatric Type 1 Diabetes Mellitus: A Prospective Blinded Speckle Tracking Stress Echocardiography Study.Diabetic cardiomyopathy: where we are and where we are going.Silent diabetic cardiomyopathy in everyday practice: a clinical and echocardiographic studyPPARs modulate cardiac metabolism and mitochondrial function in diabetes.Mammalian target of rapamycin (mTOR) inhibition with rapamycin improves cardiac function in type 2 diabetic mice: potential role of attenuated oxidative stress and altered contractile protein expression.Diabetic cardiomyopathy: An expression of stage B heart failure with preserved ejection fraction.Argatroban Attenuates Diabetic Cardiomyopathy in Rats by Reducing Fibrosis, Inflammation, Apoptosis, and Protease-Activated Receptor Expression.[Diabetes and heart failure : Update 2017].Evolution of subclinical myocardial dysfunction detected by two-dimensional and three-dimensional speckle tracking in asymptomatic type 1 diabetic patients: a long‑term follow-up study.Diastolic function deterioration in type 2 diabetes mellitus: predictive factors over a 3-year follow-up.ATF3 expression in cardiomyocytes preserves homeostasis in the heart and controls peripheral glucose tolerance.Echocardiographic feature of diabetic cardiomyopathy: where are we now?Effects of Pravastatin on Type 1 Diabetic Rat Heart with or without Blood Glycemic Control.Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes.Opening of mitoKATP improves cardiac function and inhibits apoptosis via the AKT-Foxo1 signaling pathway in diabetic cardiomyopathy
P2860
Q26775037-619E1FCC-41CA-414E-B4A3-6F08693034D4Q30391941-B1556AE0-AA97-4749-A3C5-1C8C82D87711Q33690717-B5246C59-1CF4-4AFF-A8FE-797371C488E1Q36205861-A5859637-6848-443D-862D-35F743E6B505Q37576286-9810B5DF-71B2-4E16-8A36-509D8D8D8CEFQ37583506-A0B08DAE-47EE-4776-AD95-3B4DDE96C20AQ38440130-F3C18CEE-8834-40E0-B563-FDF5DC1158DBQ40127983-A5A64F35-C9F7-4ABA-B847-004C80506D09Q40249021-D12E5A91-09AE-490D-8BEB-5A1217E043D2Q48516669-A07BEDEE-7533-4326-A003-565B7BFF3B6DQ50909669-1431013B-98AD-4F80-85CD-74A73CE0E13CQ51194041-8EE6CC3B-A2DA-41B5-BEA3-7E8AE85778F7Q52654959-953C1B91-928A-4776-BB41-3D758A785A28Q55031704-49755199-2D7F-4AB4-A603-3B4F7700C62DQ55332339-FD6EC39E-B2DD-4C92-88FF-F251CC3F1DBDQ58724803-3A9C5740-BDF2-4816-9058-0426B559B895
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Diabetic cardiomyopathy: myth or reality?
@en
type
label
Diabetic cardiomyopathy: myth or reality?
@en
prefLabel
Diabetic cardiomyopathy: myth or reality?
@en
P1476
Diabetic cardiomyopathy: myth or reality?
@en
P2093
Laura Ernande
P304
P356
10.1016/J.ACVD.2011.11.007
P577
2012-03-09T00:00:00Z